First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage

BACKGROUND: Conflicting findings with regard to the teratogenic risks of first trimester use of paroxetine have prompted the FDA, Health Canada, and the manufacturer of the drug to issue warnings against its use during pregnancy. Given that untreated depression during pregnancy can lead to deleterio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Birth defects research. Part B. Developmental and reproductive toxicology 2007-02, Vol.80 (1), p.18-27
Hauptverfasser:	Bérard, Anick, Ramos, Élodie, Rey, Évelyne, Blais, Lucie, St.-André, Martin, Oraichi, Driss
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities, Drug-Induced - etiology Adolescent Adult Antidepressive Agents, Second-Generation - adverse effects dosage Dose-Response Relationship, Drug Female Heart Defects, Congenital - chemically induced Humans major cardiac malformations major congenital malformations Middle Aged paroxetine Paroxetine - adverse effects Pregnancy pregnancy registry Pregnancy Trimester, First Serotonin Uptake Inhibitors - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!